EQS-Adhoc IGEA to update on business combination - Seite 2

Nachrichtenquelle: EQS Group AG
15.02.2021, 00:25  |  211   |   |   

Prof. Antonello Sannia, Chairman of the Scientific Advisory Board of BSNR "Our hemp flower oleolite is very rich in CBD, with a THC concentration well within limits. The therapeutic potential of CDB is well established, in particular with regard to its anxiolytic, antipsychotic and pain-relieving properties. It also presents anti-inflammatory, antioxidant and neuroprotective effects and has a proved usefulness in various health issues including Alzheimer's disease, Parkinson's disease, anxiety-depressive syndrome, cerebral ischemia, rheumatoid arthritis, and many other inflammatory diseases".

"We are strongly committed to close this combination to create one of the leading European players in the CBD industry, with the confidence of a favorable market momentum that supports our strategy. Thanks to this combination, we will enforce our product development and commercial capabilities, also leveraging on the synergies with the Alzheimer's prevention set started by IGEA. We are confident that their team will perfectly complement our capabilities" said Maurizio Scuotto, CEO and board member of BSNR.

Vincenzo Moccia, CEO of IGEA "We engaged strongly in this combination because we believe in synergies and advantages for both parties and all stakeholders. The positive expectation boosts our commitment".

About IGEA
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. Med-tech products focuses on selected solutions and specialties. IGEA commercializes dry aerosol generators for air and inanimate environmental surfaces sanitization and sterilization and air purification devices.

Seite 2 von 5
IGEA Pharma Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf

Diesen Artikel teilen

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



EQS-Adhoc IGEA to update on business combination - Seite 2 EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous IGEA to update on business combination 15-Feb-2021 / 00:25 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this …


Nachrichten des Autors